Quantcast

Cost Sharing of Disease-Modifying Treatments (DMTs) as Policy Lever to Improve DMTs’ Access in Multiple Sclerosis

Research paper by Hui Shao, Charles Stoecker; Alisha M. Monnette; Lizheng Shi

Indexed on: 28 Feb '18Published on: 26 Feb '18Published in: Value in Health



Abstract

Publication date: Available online 8 January 2018 Source:Value in Health Author(s): Hui Shao, Charles Stoecker, Alisha M. Monnette, Lizheng Shi Objectives To understand the nonlinear relationship between out-of-pocket (OOP) payments and disease-modifying treatment (DMT) use and adherence, primarily to pinpoint the threshold at which the use of DMTs becomes price sensitive. Methods Individuals with more than two multiple sclerosis (MS) diagnoses (International Classification of Diseases, Ninth Revision code 340) were identified from the MarketScan database (2006–2009). Heterogeneity in treatment was normalized by calculating an annual OOP payment as the average OOP payment for purchasing a fixed basket of DMTs at the insurance plan level. A local linear regression with a model-based recursive partitioning algorithm was applied to explore the relationship between OOP and consequently lower DMT use and adherence as measured by days covered by DMT. Results We identified the inflection points in annual OOP payments as $442 for DMT use and $890 for DMT adherence. For patients with annual OOP payments of more than $442, a $100-increase in OOP payment was associated with a decline of 0.6% in DMT use; for annual OOP payments of more than $890, a $100-increase in OOP payment was associated with two fewer days of DMT treatments. Conclusions Although the use of DMTs and DMT adherence appeared unassociated with OOP payment below $442 and $890, respectively, an excessive OOP payment was a barrier to DMT access. This information can inform maximum monthly and yearly payment caps when designing valued-based insurance plans.